Immuno-Oncology

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age of immunotherapy.

Adding ivonescimab to chemotherapy improved PFS for patients with EGFR-mutated non–small cell lung cancer after treatment with a third-generation TKI.

Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Yelena Shames, MSA, ACNP-BC, CNRN, argues that frequent hematologic evaluations may not always be warranted with immune checkpoint inhibitors.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

A retrospective cohort demonstrated that patients who are treated with antibiotics within 1 year before immune checkpoint inhibitor therapy may experience worse overall survival.

Lindsay Diamond, MSN, AGNP-C, AOCNP, unpacks the significance of recent advances in the bladder cancer space.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Atezolizumab did not yield a significant improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

There continues to be an unmet need for effective and tolerable frontline treatments for patients with squamous cell carcinoma of the head and neck, according to investigators.

For patients with head and neck cancer who cannot access full-dose checkpoint inhibitors, adding low-dose nivolumab to metronomic chemotherapy may represent an acceptable alternative treatment approach.

Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

Patients with non–small cell lung cancer who received toripalimab experienced significant improvements in progression-free survival and overall survival.

The overall survival benefit associated with pembrolizumab for patients with head and neck cancer continued to be observed at a 4-year follow-up of the KEYNOTE-048 trial.

Neoadjuvant chemotherapy allowed 79% of patients with early-stage I/IIA rectal cancer to pursue organ-sparing excision surgery, potentially preserving their quality of life and bowel function.

Six-year follow-up data showed an overall survival rate of 89% among patients with follicular lymphoma who received either lenalidomide plus rituximab or immunochemotherapy.

Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.

Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting